摘要
Immune checkpoint blockade therapy,which targets T cells to enhance the antitumor immune response,has become a promising treatment for many cancer types1,2.Till now,a total of 6 checkpoint inhibitors targeting cytotoxic T lymphocyte antigen-4(CTLA-4)。
基金
supported by National Natural Science Foundation of China (Grant No. 81802813)
Scientific Research Seed Fund of Peking University First Hospital (Grant No. 2018SF039)